Welcome to our dedicated page for Acadia Pharmaceuticals news (Ticker: ACAD), a resource for investors and traders seeking the latest updates and insights on Acadia Pharmaceuticals stock.
News and updates for Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) focus on its activities in neurological and rare diseases, including commercial performance and clinical development. Company press releases highlight revenue trends from its marketed medicines NUPLAZID for hallucinations and delusions associated with Parkinson’s disease psychosis and DAYBUE for Rett syndrome, as well as guidance ranges for total revenues and net product sales.
Investors following ACAD news can see announcements of quarterly financial results, participation in major healthcare and investor conferences, and business updates presented at events such as the J.P. Morgan Healthcare Conference. These updates often describe how NUPLAZID and DAYBUE are performing commercially and how Acadia views the growth outlook for its neurology and neuro‑rare franchises.
Acadia’s news flow also covers regulatory and clinical milestones. Examples include U.S. Food and Drug Administration approval of DAYBUE STIX, a powder formulation of trofinetide for oral solution for Rett syndrome in adults and pediatric patients 2 years of age and older, approval of DAYBUE oral solution by the Ministry of Health in Israel, and progress toward regulatory opinions and late‑stage studies for trofinetide in other regions. The company issues updates on its pipeline, such as timelines for Phase 2 and Phase 3 trials of remlifanserin (ACP‑204) in Alzheimer’s disease psychosis and Lewy body dementia psychosis, and data presentations on ACP‑711 and NUPLAZID at scientific congresses.
Readers of this ACAD news page can use it to track Acadia’s financial disclosures, regulatory approvals, clinical trial readouts, and strategic commentary from management over time. The news archive provides context on how the company’s commercial portfolio and pipeline in central nervous system and neuro‑rare diseases are evolving.
Acadia Pharmaceuticals Inc. reported full-year 2022 net sales of $517.2 million, a 7% increase from 2021, driven by strong demand for NUPLAZID®. The fourth-quarter sales reached $136.5 million, up 4% year-over-year. The company anticipates a transformative 2023, with a PDUFA action date for trofinetide set for March 12, 2023. However, Acadia reported a net loss of $216 million for 2022, increasing from $167.9 million the previous year. For 2023, projected net sales for NUPLAZID are between $520 million to $550 million.
Acadia Pharmaceuticals (NASDAQ: ACAD) will announce its fourth quarter and full year 2022 financial results on
The company will host a conference call and webcast that same day at
Acadia is focused on neuroscience breakthroughs, developing therapies for conditions like Parkinson's disease psychosis, schizophrenia, and Alzheimer's disease psychosis.
Acadia Pharmaceuticals announced the grant of inducement awards on February 10, 2023, to 19 new employees under its 2023 Inducement Plan. This includes non-qualified stock options for 310,065 shares and 97,251 restricted stock units (RSUs). The options have an exercise price of $18.97 and will vest over four years. Notably, Douglas J. Williamson, the new Executive VP of Research & Development, received options for 237,296 shares and RSUs for 50,655 shares. These awards are designed to incentivize new hires and comply with Nasdaq regulations.
Acadia Pharmaceuticals has appointed Dr. Doug Williamson as Executive Vice President, Head of Research and Development. Dr. Williamson, succeeding Dr. Srdjan Stankovic, brings over 20 years of neuroscience R&D experience, most recently serving as Chief Medical Officer at Avadel Pharmaceuticals. His leadership is expected to play a crucial role as Acadia prepares for the potential approval of trofinetide for Rett syndrome and advances its clinical programs. This strategic move aims to strengthen Acadia's position in the neuroscience market during a pivotal time.
Acadia Pharmaceuticals announced positive findings from a retrospective analysis published in Drug Safety, indicating a lower mortality risk in Parkinson's disease psychosis (PDP) patients treated with NUPLAZID® (pimavanserin) compared to other atypical antipsychotics. The study, based on Medicare claims data, showed a hazard ratio for all-cause mortality of 0.78 for NUPLAZID. Results were consistent across various patient subgroups, including those in long-term care facilities. NUPLAZID remains the only FDA-approved treatment for PDP, highlighting its significance in managing this challenging condition.
Acadia Pharmaceuticals will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 9:00 a.m. PT. The presentation will include a live Q&A session and can be accessed via their website under the investors section. An archived recording will be available for one month post-event. Acadia has over 25 years in healthcare, focusing on breakthroughs in neuroscience, including therapies for Parkinson's disease psychosis and ongoing clinical developments for schizophrenia and Rett syndrome.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) will participate in two investor conferences. The first is the Guggenheim 4th Annual Immunology and Neurology Day on November 14, 2022, in New York, NY. The second is the J.P. Morgan Equity Opportunities Forum on November 15, 2022, in Miami, FL. A live webcast of Acadia's presentation at the Guggenheim conference will be available at www.acadia.com at 9:35 a.m. Eastern Time.
Acadia focuses on neuroscience breakthroughs, including therapies for Parkinson’s disease psychosis and negative symptoms of schizophrenia.
Acadia Pharmaceuticals (Nasdaq: ACAD) reported third-quarter 2022 net sales of $130.7 million for NUPLAZID, representing a 1% decline year-over-year, though driven by 2% sequential demand growth. A Prescription Drug User Fee Act action date is set for March 12, 2023 for trofinetide, aimed at treating Rett syndrome, with the FDA granting priority review. R&D expenses rose to $81.3 million, influenced by milestone payments. Net loss for the quarter expanded to $27.2 million, attributed to increased R&D and compensation expenses. Cash reserves stood at $436.6 million as of September 30, 2022.
Acadia Pharmaceuticals (NASDAQ: ACAD) announced that Dr. Srdjan Stankovic will retire as President at year-end but will continue as an advisor. Dr. Stankovic has been pivotal in advancing Acadia, particularly with the approval of NUPLAZID for Parkinson’s disease psychosis and ongoing drug applications for Rett syndrome and schizophrenia. CEO Steve Davis praised his contributions and the company's exciting R&D portfolio. Acadia remains focused on developing solutions for unmet medical needs in neuroscience.
Acadia Pharmaceuticals will report its third quarter 2022 financial results on November 2, 2022, after markets close. A conference call and webcast will follow at 4:30 p.m. Eastern Time to discuss the financial results and business operations. Acadia has developed the first approved therapy for hallucinations and delusions related to Parkinson's disease psychosis, with ongoing efforts in treating dementia-related psychosis and symptoms in schizophrenia and Rett syndrome. For further details, visit www.acadia.com.
FAQ
What is the current stock price of Acadia Pharmaceuticals (ACAD)?
What is the market cap of Acadia Pharmaceuticals (ACAD)?
